로딩 중…
지수 로딩 중…
Aminologics Co.,Ltd.
074430· KOSDAQ· Materials· Materials
₩1,120-7.36%
2026-06-19
Price Chart
Aminologics Co.,Ltd.+16.06%
Financials
Investment Metrics(as of 2026-06-19)
| Metric | Value |
|---|---|
| Size | |
| Market Cap | 98.37B KRW |
| Revenue | 22.68B KRW |
| Net Income | 2.26B KRW |
| Total Assets | 87.63B KRW |
| Net Assets | 57.11B KRW |
| Employees | 38 |
| Value | |
| P/E | 43.55x |
| P/B | 1.72x |
| P/S | 4.34x |
| EV/EBITDA | 22.31x |
| Profitability | |
| ROE | 3.96% |
| ROA | 2.58% |
| Op. Margin | 16.37% |
| Revenue Growth | 13.87% |
| Earnings Growth | -54.19% |
| Financial Health | |
| Debt Ratio | 153.43% |
| Total Debt | 15.93B KRW |
| Cash | 31.48B KRW |
| Current Ratio | 2.75x |
| Net Debt/EBITDA | -4.19x |
| Performance | |
| 1Y Return | 16.06% |
| 1M Return | -7.97% |
| From 52W High | -42.27% |
| 1Y MDD | -41.78% |
| Trading | |
| Volume | 104,695 shares |
| Foreign Own. | 2.13% |
| Per Share | |
| EPS | 26 KRW |
| BPS | 650 KRW |
Company Info
Aminologics, established in 1997 and KOSDAQ listed in 2004, is a small and medium-sized venture enterprise. The company acquired the active pharmaceutical ingredient (API) business rights from Sam-O Pharmaceutical in 2015, supplying APIs for stroke, eye diseases, and dermatitis to domestic pharmaceutical companies. Since 2009, Aminologics has been developing various products, including D-Serine, through its amino acid derivative business. Recognized for its quality by global customers, the company is actively engaged in research and development to capture the peptide new drug market, receiving new development requests. Aminologics is headquartered in Gangnam-gu, Seoul.